Skip to content

Effect of Swisse Ultiboost High Potency fish oil + CoQ10 on microvascular function

Effect of Swisse Ultiboost High Potency fish oil + CoQ10 on microvascular function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102402
Enrollment
Unknown
Registered
2025-05-14
Start date
2025-05-19
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Control Group:Take 2 capsules containing corn oil daily
Intervention Group:Capsules containing mixed fish oil 2 capsules per day

Sponsors

Medical College of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 30-70 years old; 2. Patients with hypertension (systolic pressure >= 140mmHg or diastolic pressure >= 90mmHg); 3. People with normal cognitive function; 4. Current residence in Huaiyin District, Tianqiao District, or Shizhong District of Jinan City; 5. Voluntarily sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in this study; 2. Communication barriers and inability to cooperate with researchers; 3. Those with a history of abuse or addiction to alcohol, analgesics or other drugs; 4. Have participated in other intervention experiments or taken relevant nutritional supplements (such as fish oil, krill oil, algal oil, astaxanthin, resveratrol, coenzyme Q10, etc.) within 3 months before being included in the study; 5. Has cardiomyopathy, acute coronary syndrome, severe valvular heart disease, grade three or four heart failure, and severe arrhythmia; 6. Has undergone coronary artery surgery or heart surgery within the last three months; 7. Had undergone brain surgery within the last three months; 8. Cerebral infarction and cerebral hemorrhage have occurred in the past three months. 9. There are cerebral small vessel diseases and cerebral arteriovenous malformations; 10. People with mental disorders, such as a history of epilepsy, Parkinson's disease or myasthenia gravis, etc. 11. Those with impaired liver or kidney functions; 12. Pregnant or lactating women; Youdaoplaceholder 13. Patients with malignant tumors; 14. People who are allergic to food or medicine.

Design outcomes

Primary

MeasureTime frame
Microvessel Cerebral Blood Flow;Mean transit time;Blood flow before forearm ischemia;Reactive hyperemia RH;Resting-State Functional Magnetic Resonance Imaging;T1-Weighted Imaging;Diffusion Tensor Imaging;Diastolic/ systolic velocity ratio (DSVR);Average peak velocities,APV;Diastolic Deceleration Rate (DDR);Peak Diastolic Velocity,PDV;Maximal blood flow after forearm ischemia;Duration of reactive hyperemia;area under the curve AUC;

Secondary

MeasureTime frame
Diastolic reduction time;Free fatty acids, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides;Coronary artery S/D ratio;

Countries

China

Contacts

Public ContactLi Kelei

Qingdao University

likelei@qdu.edu.cn+86 187 6590 3155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026